

6 October 2026

To

BSE Limited

25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 543064

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Disclosure regarding ESG Rating by Crisil ESG Rating & Analytics Limited

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations'), read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, we wish to inform that Crisil ESG Ratings & Analytics Limited (Crisil ESG Ratings) has voluntarily assigned an ESG Rating of "Crisil ESG 61 (Strong)" and Core ESG Rating of "Crisil Core ESG 67 (Strong)" to the Company.

The link for the rating as published by Crisil ESG Ratings:

<https://www.crisilesg.com/en/home/esg-ratings.html>

Please note that the Company has not engaged Crisil ESG Ratings for the ESG Rating. The rating has been independently determined by Crisil ESG Ratings based on publicly available information pertaining to the Company.

This is for your information and record.

Thanking You.

Yours faithfully,

For **Cohance Lifesciences Limited**

(formerly, Suven Pharmaceuticals Limited)

Sisira

Kumar

Mishra

Sisir K. Mishra

Company Secretary & Compliance Officer

Digitally signed by
Sisira Kumar
Mishra
Date: 2026.10.06
15:15:15 +05'30'

Cohance Lifesciences Limited

(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

